EA201991790A1 - Терапевтические препараты апремиласта для местного применения - Google Patents

Терапевтические препараты апремиласта для местного применения

Info

Publication number
EA201991790A1
EA201991790A1 EA201991790A EA201991790A EA201991790A1 EA 201991790 A1 EA201991790 A1 EA 201991790A1 EA 201991790 A EA201991790 A EA 201991790A EA 201991790 A EA201991790 A EA 201991790A EA 201991790 A1 EA201991790 A1 EA 201991790A1
Authority
EA
Eurasian Patent Office
Prior art keywords
apremilastic
therapeutic
local use
methods
relates
Prior art date
Application number
EA201991790A
Other languages
English (en)
Inventor
Венката Ноокараджу Среедхарала
Original Assignee
Сарудбхава Формулатионс Привате Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сарудбхава Формулатионс Привате Лимитед filed Critical Сарудбхава Формулатионс Привате Лимитед
Publication of EA201991790A1 publication Critical patent/EA201991790A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
    • A61K8/4913—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having five membered rings, e.g. pyrrolidone carboxylic acid
    • A61K8/492—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having five membered rings, e.g. pyrrolidone carboxylic acid having condensed rings, e.g. indol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Birds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)

Abstract

Настоящее изобретение относится к препаратам для местного применения, содержащим апремиласт. Изобретение также относится к способам получения таких препаратов и способам их использования при лечении кожных заболеваний или нарушений, таких как псориаз, дерматоз, экзема, розовые угри, обыкновенные угри, аллергии, контактный и атопический дерматит, зуд, себорея, рак кожи, воспаление и другие сопутствующие заболевания кожи.
EA201991790A 2017-01-27 2018-01-24 Терапевтические препараты апремиласта для местного применения EA201991790A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201741003041 2017-01-27
PCT/IN2018/050038 WO2018138737A1 (en) 2017-01-27 2018-01-24 Therapeutic topical compositions of apremilast

Publications (1)

Publication Number Publication Date
EA201991790A1 true EA201991790A1 (ru) 2020-04-03

Family

ID=62979069

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201991790A EA201991790A1 (ru) 2017-01-27 2018-01-24 Терапевтические препараты апремиласта для местного применения

Country Status (10)

Country Link
US (1) US20190374508A1 (ru)
EP (1) EP3573599A4 (ru)
JP (2) JP2020505469A (ru)
CN (1) CN110352052A (ru)
AU (2) AU2018213249A1 (ru)
BR (1) BR112019015596A2 (ru)
CA (1) CA3051553A1 (ru)
EA (1) EA201991790A1 (ru)
WO (1) WO2018138737A1 (ru)
ZA (1) ZA201905489B (ru)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190060221A1 (en) * 2017-08-22 2019-02-28 Cadila Healthcare Limited Topical formulation of apremilast
EP3853204A4 (en) * 2018-09-21 2022-06-22 Apramitha Innovations Private Limited IMPROVED AND STABLE APREMILAST PHARMACEUTICAL COMPOSITIONS
IN201941006472A (ru) * 2019-02-19 2019-04-05
WO2020219470A1 (en) * 2019-04-22 2020-10-29 Starton Therapeutics, Inc. Continuous delivery of lenalidomide and other immunomodulatory agents
WO2021090301A1 (en) * 2019-11-06 2021-05-14 Sarudbhava Formulations Private Limited Apremilast low-dose topical pharmaceutical compositions
WO2021100051A1 (en) * 2019-11-24 2021-05-27 Sol-Gel Technologies Ltd. Treatment of skin disorders with topical compositions comprising tapinarof and a pde4 inhibitor
US20230149352A1 (en) * 2020-04-22 2023-05-18 Apramitha Innovations Private Limited Uses of apremilast
EP4259125A1 (en) * 2020-12-09 2023-10-18 Apramitha Innovations Private Limited Apremilast ophthalmic compositions
CN113712918A (zh) * 2021-10-28 2021-11-30 济南纽华医药科技有限公司 一种阿普斯特微乳及其制备方法
CN114432242B (zh) * 2022-02-28 2023-01-17 重庆化工职业学院 一种阿普斯特纳米晶组合物及制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6962940B2 (en) * 2002-03-20 2005-11-08 Celgene Corporation (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
US20070155791A1 (en) * 2005-12-29 2007-07-05 Zeldis Jerome B Methods for treating cutaneous lupus using aminoisoindoline compounds
WO2012121988A2 (en) 2011-03-07 2012-09-13 Celgene Corporation Methods for treating diseases using isoindoline compounds
JP6022548B2 (ja) * 2011-04-28 2016-11-09 セルジーン コーポレイション Ｐｄｅ４阻害剤を自己免疫疾患及び炎症性疾患の治療及び管理に使用する方法及び組成物
EP2730278A1 (en) 2012-11-08 2014-05-14 Ratiopharm GmbH Composition melt
CA2928962A1 (en) * 2013-10-28 2015-05-07 Morten SLOTH WEIDNER Dermatological compositions
JP6643228B2 (ja) 2014-06-26 2020-02-12 ジャパンエレベーターサービスホールディングス株式会社 遠隔監視支援装置
WO2016198469A1 (en) * 2015-06-09 2016-12-15 Hpf Ip Holding S.A. Penetration of alpha-hydroxy acids from water-free emulsions
US9979239B2 (en) 2016-03-18 2018-05-22 Global Energy Transmission, Co. Systems and methods for wireless power transferring
BR112018070155B1 (pt) * 2016-03-30 2023-10-24 Sarudbhava Formulations Private Limited Composições farmacêuticas de apremilast
BR112018076114A2 (pt) 2016-06-15 2019-03-26 Torrent Pharmaceuticals Limited composições tópicas de apremilast

Also Published As

Publication number Publication date
CN110352052A (zh) 2019-10-18
WO2018138737A1 (en) 2018-08-02
JP2020505469A (ja) 2020-02-20
EP3573599A1 (en) 2019-12-04
US20190374508A1 (en) 2019-12-12
AU2018213249A1 (en) 2019-09-19
BR112019015596A2 (pt) 2020-03-17
AU2023266295A1 (en) 2023-12-07
EP3573599A4 (en) 2020-12-09
JP2023022177A (ja) 2023-02-14
CA3051553A1 (en) 2018-08-02
ZA201905489B (en) 2020-07-29

Similar Documents

Publication Publication Date Title
EA201991790A1 (ru) Терапевтические препараты апремиласта для местного применения
PH12018502429A1 (en) Antibody molecules for cancer treatment
MX2021001439A (es) Composiciones y metodos para el tratamiento de la disfuncion de la glandula de meibomio.
EA201890218A1 (ru) Ретиноидные композиции для местного применения
MX2022001607A (es) Composiciones y metodos para tratar la psoriasis y la dermatitis atopica usando prevotella histicola.
MX2018002067A (es) Manejo con tetraciclina de dermatosis asociada con inhibidor de egfr.
CA3006294A1 (en) Combinations of rapamycin and metformin for the treatment of joint and skin diseases
PH12015501552A1 (en) Androgen receptor modulator and uses thereof
BR112018069533A2 (pt) tratamento de condições alérgicas oculares com ciclodextrinas
BR112017018964A2 (pt) uso de plinabulin e métodos para tratar tumor cerebral
GB201307157D0 (en) Biophotonic compositions, kits and methods
MX362185B (es) Composiciones y tratamiento para enfermedades y trastornos del ojo.
MX2023002076A (es) Conjugado de polimero util para tratar tumores ocasionados por disfuncion metabolica.
FI20115135L (fi) Mikrofibrilloitu selluloosa käytettäväksi erityisesti atooppisen ihotulehduksen ja psoriasiksen hoidossa
BR112017009552A2 (pt) métodos para alvejar o controle transcricional em regiões de super-realçador
ZA202211665B (en) Ammonia oxidizing bacteria for treatment of acne
BR112023005160A2 (pt) Terapia de combinação para o tratamento de câncer
IN2015DN00370A (ru)
EA201791814A1 (ru) Имидазолильные трициклические еноны как антиоксидантные модуляторы воспаления
MX2019002047A (es) Metodos y composiciones para tratar infecciones fungicas cutaneas.
MX2021003006A (es) Bacterioterapia contra proprionibacterium acnes para el tratamiento de acne.
MX2021007271A (es) Nuevas moleculas de acido nucleico conjugado y sus usos.
TN2015000142A1 (en) Use of pidotimod to treat psoriasis
TW201613599A (en) Use of composition for manufacture of medicament for suppressing androgen receptor related function and treatment of androgen receptor related disease
MX2018015240A (es) Composiciones que comprenden timolol y su uso en el tratamiento de rosacea mediante administracion topica.